Brief: TELA Bio Highlights Results from Studies on Benefits of OviTex Reinforced Tissue Matrix in Hernia Repairs
04/08/2022 12:53
Aug 4 (Reuters) - TELA Bio Inc TELA.O :
* TELA BIO INC - 24-MONTH BRAVO STUDY RESULTS SHOWED A 2.6%
RECURRENCE RATE IN DIVERSE CLINICAL SCENARIOS
* TELA BIO INC - ROBOTIC REINFORCED BIOLOGIC AUGMENTED
REPAIR
(REBAR) STUDY SHOWED A 1.9% RECURRENCE RATE AT TWO-YEAR MARK
Source text for Eikon: ID:nGNX46XJP9
Further company coverage: TELA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TELA Bio
See all newsTELA Bio Q1 revenue growth beats estimates, loss widens
Brief: TELA Bio Q1 Revenue USD 19.059 Million Vs. IBES Estimate USD 18.6 Million
Brief: Tela Bio Announces Inducement Grants Under Nasdaq Listing Rule
Medical device maker Becton Dickinson sued over alleged hernia mesh monopoly
Brief: TELA Bio Announces Pricing Of $13.0 Million Underwritten Registered Direct Offering Of Common Stock And Pre-Funded Warrants